Rates of Self-Directed Perioperative Cannabidiol use in Patients Undergoing Total Hip or Knee Arthroplasty

Abstract

Aim: To evaluate the prevalence of self-directed cannabidiol (CBD) use in patients with end-stage degenerative hip and knee arthritis who underwent total hip arthroplasty and total knee arthroplasty. Materials & methods: Anonymous surveys for 109 patients were completed at 6 weeks follow-up after either total hip arthroplasty or total knee arthroplasty at a single tertiary care US orthopedic hospital. Results: Within the perioperative window encompassing both preoperative and postoperative periods, 22% (95% CI: 14–30%) of patients used CBD. Conclusion: There was no difference in pain satisfaction between patients who used CBD and patients who did not. Given high rates of self-directed perioperative CBD use and the mixed body of evidence, further research is needed to better understand whether CBD is safe and effective.

Lay abstract

Aim: To evaluate the self-guided usage rate of cannabidiol (CBD) in patients with hip and knee arthritis who underwent hip and/or knee replacement surgery. Materials & methods: Anonymous surveys for 109 patients were completed 6 weeks after either hip or knee replacement surgery at a large US orthopedic hospital. Results: Among the 109 patients who underwent hip and/or knee replacement surgery, 22% (95% CI: 14–30%) of patients used CBD. Conclusion: There was no difference in pain satisfaction between patients who used CBD and patients who did not. Given high rates of self-guided CBD use among patients undergoing hip or knee replacement surgery together with the mixed body of research, further research is needed to better understand whether CBD is safe and effective.

Keywords::

• cannabidiol
• CBD
• hip replacement
• knee replacement

Supplementary data

To view the supplementary data that accompany this paper please visit the journal website at: www.tandfonline.com/doi/suppl/10.2217/pmt-2021-0018

Financial & competing interests disclosure

P Sculco reports personal fees and nonfinancial support from Medical Device Business Services, Inc., LimaCorporate S.p.A, Intellijoint Surgical, Lima USA, Zimmer Biomet, Depuy Synthes EOS Imaging and Insight Medical Systems, outside the submitted work. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

This study was deemed exempt by the Hospital for Special Surgery Institutional Review Board as no identifiable patient data were collected or used. The authors state that they have obtained appropriate Institutional Review Board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.

Additional information

Funding

P Sculco reports personal fees and nonfinancial support from Medical Device Business Services, Inc., LimaCorporate S.p.A, Intellijoint Surgical, Lima USA, Zimmer Biomet, Depuy Synthes EOS Imaging and Insight Medical Systems, outside the submitted work. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.